Survodutide | High-quality freeze-dried powder | Best-selling peptide | Available for immediate delivery

The dual agonist of glucagon receptor/GLP-1 receptor (GCGR/GLP-1R), suvadipine (BI 456906), has been recognized as a breakthrough therapy by the Drug Evaluation Center of the National Medical Products Administration of China. It is used for the treatment of metabolic dysfunction-related steatohepatitis (MASH). Suvadipine is a unique mechanism of action glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist. The glucagon receptor agonist component in suvadipine can increase energy consumption and directly act on the liver, helping to improve liver fibrosis. The GLP-1 agonist component can effectively reduce appetite and increase satiety simultaneously.

Dual-target potent activation
The synergistic activation of both GLP-1R and GCGR receptors is more effective than that of a single GLP-1 peptide.

Strong fat loss and weight reduction
Inhibiting appetite, reducing food intake; enhancing basal metabolism, accelerating fat breakdown, rapidly

reducing body fat and weight.

Controlling blood sugar and lowering blood sugar
Improving insulin resistance, stabilizing blood sugar, reducing glycosylated hemoglobin, suitable for metabolic and hypoglycemic research.

Improving liver metabolism
Targeted reduction of liver fat accumulation, improving fatty liver and MASH liver injury.
Regulating lipid metabolism

Reducing triglycerides and cholesterol, improving overall lipid metabolism disorder.

Long-acting sustained-release
Fatty acid acylation modification, with an extremely long half-life, taking effect once a week, with long-lasting effects.

Regulating energy balance
Reducing calorie intake + increasing energy expenditure, bidirectional regulation, improving obesity metabolic syndrome.